The assumption was that whatever the risks of legalizing therapeutic MDMA, the crisis of PTSD gripping the country (and doing ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for ...

Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD. Drugmaker Lykos ...

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024.

Drugmaker Lykos Therapeutics had asked the FDA to approve its MDMA capsules as part of a therapy regimen they argued could be a breakthrough for treating challenging cases of PTSD. Lykos said the ...

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

In June 2024, an FDA advisory committee voted overwhelmingly against the idea that the relevant clinical trials had proved the efficacy of MDMA for the treatment of PTSD. Just as decisively ...

In view of the ... in PTSD symptoms among military veterans, particularly in reducing avoidance behaviors and hyper-arousal – key components of PTSD. Comparative research between MDMA and ...

Two small studies submitted to the FDA suggested combining MDMA with talk therapy led to significant easing of PTSD symptoms.

Some researchers call MDMA an “empathogen” or a “feeling enhancer.” PTSD affects between 9 million to 13 million people annually in the U.S., and no novel treatments for the condition have been ...

MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to ...